ImmuneOnco Biopharmaceuticals (Shanghai) Full Year 2023 Earnings: CN¥1.05 loss per share (vs CN¥1.21 loss in FY 2022)

Simply Wall St·03/26/2024 23:14:17

Listen to the news

ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) Full Year 2023 Results

Key Financial Results

Net loss: CN¥379.5m (loss narrowed by 5.8% from FY 2022).
CN¥1.05 loss per share (improved from CN¥1.21 loss in FY 2022).

earnings-and-revenue-history — SEHK:1541 Earnings and Revenue History March 26th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

ImmuneOnco Biopharmaceuticals (Shanghai) Earnings Insights

Looking ahead, revenue is expected to decline by 119% p.a. on average during the next 2 years, while revenues in the Biotechs industry in Hong Kong are expected to grow by 25%.

Performance of the Hong Kong Biotechs industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with ImmuneOnco Biopharmaceuticals (Shanghai) (at least 1 which is a bit unpleasant), and understanding them should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

FAQ

Fee Schedule Open Account Deposit & Withdrawal Trading

Terms & Conditions

Client Agreement Privacy Policy Data Disclaimer Security Tips

About Webull

About us Webull Promotions Contact information Announcements

Service Email : service@webull.hkBusiness Cooperation : marketinghk@webull.hk

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
② More than 40M Downloads Globally : data based on Webull Technologies Limited's internal statistics as of July 14, 2023.
③ Pre-market (4:00 AM - 9:30 AM ET) , after-hours (4:00 PM - 8:00 PM ET) .
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.

Language

English